StockIQ.tech4D Molecular Therapeutics, Inc. (FDMT) Stock Analysis
Free AI-powered analysis and research for 4D Molecular Therapeutics, Inc. stock
Sector: Healthcare
Full FDMT report
4D Molecular Therapeutics, Inc. (FDMT) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze FDMT Now →📰 Latest Update
4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Mon, November 2, 2026 at 2:00 PM UTC 4 min read
4D Molecular Therapeutics, Inc. (FDMT) is anticipated to report a quarterly loss of $1.04 per share, reflecting a year-over-year decline of 3%, while revenues are expected to surge by 3777.8% to $3.49 million. The company has a positive Earnings ESP of +4.35%, suggesting analysts are optimistic about its earnings prospects, despite a Zacks Rank of #3. The article highlights that actual results compared to estimates will significantly influence the stock's near-term movement.